Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

Bruno C. Medeiros, Steven M. Chan, Naval G. Daver, Brian Jonas, Daniel A. Pollyea

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

Original languageEnglish (US)
JournalAmerican Journal of Hematology
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this